AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37499590 — intervention group
Group type: EXPERIMENTAL
Intervention: Bhramari Pranayama
Number of subjects: 100
Study 37499590 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 33053131 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial resistance testing
Number of subjects: 79
Study 33053131 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance to specific antimicrobials
Number of subjects: 79
Study 33053131 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of resistance genes
Number of subjects: 79
Study 33053131 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of virulence factors
Number of subjects: 79
Study 32517072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education provided at schools
Number of subjects: 1360
Study 32517072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition knowledge scores
Number of subjects: 1360
Study 32517072 — intervention group
Group type: EXPERIMENTAL
Intervention: Food items sold at schools
Number of subjects: 1360
Study 32517072 — intervention group
Group type: EXPERIMENTAL
Intervention: Government national school meal program
Number of subjects: 1360
Study 32517072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition assessment as part of the Integrated School Health Program
Number of subjects: 1360
Study 32517072 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' nutrition training
Number of subjects: 1360
Study 32517072 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge questions poorly answered
Number of subjects: 1360
Study 35777455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke web browser extension for online grocery shopping that highlights sodium content and suggests lower-sodium alternatives
Number of subjects: 1966
Study 35777455 — intervention group
Group type: COMPARATOR
Intervention: Usual online shopping (control group)
Number of subjects: 1966
Study 35777455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke web browser extension
Number of subjects: 1966
Study 34126974 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine (CAM) modalities
Number of subjects: 8395132
Study 34126974 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal teas, relaxation techniques, detoxifying diet, dietary supplements (excluding vitamins and minerals), reflexology
Number of subjects: 8395132
Study 34126974 — intervention group
Group type: EXPERIMENTAL
Intervention: Females, under age 30, with higher education, higher income, and self-reported poor health
Number of subjects: 8395132
Study 32616128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ablation (EA) combined with radiofrequency ablation (RFA)
Number of subjects: 98
Study 32616128 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 98
Study 35077042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural 2-dimensional transthoracic echocardiography (2DTTE) guided right ventricular lead placement (Group 1)
Number of subjects: 111
Study 35077042 — intervention group
Group type: COMPARATOR
Intervention: Non-echo guided implantation (Group 2)
Number of subjects: 111
Study 33516027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary CP content of 100 g CP/kg DM
Number of subjects: 48
Study 33516027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary CP content of 120 g CP/kg DM
Number of subjects: 48
Study 33516027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary CP content of 140 g CP/kg DM
Number of subjects: 48
Study 33578224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application group (intervention)
Number of subjects: 96
Study 33578224 — intervention group
Group type: COMPARATOR
Intervention: Control standard care group (control)
Number of subjects: 96
Study 35841056 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral RT+MT
Number of subjects: 96
Study 35841056 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral RT+BAT
Number of subjects: 96
Study 35841056 — intervention group
Group type: COMPARATOR
Intervention: bilateral RT+IOT
Number of subjects: 96
Study 32588050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 10g TID for 48 hours followed by maintenance therapy with SZC QD for ≤29 days
Number of subjects: 1278
Study 32588050 — intervention group
Group type: COMPARATOR
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 1278
Study 32237024 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulphate (MgSO4) - loading dose of 5 g followed by 1 g/hour
Number of subjects: 560
Study 32237024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 35987083 — intervention group
Group type: EXPERIMENTAL
Intervention: MIACT (Motivational Interviewing plus Acceptance and Commitment Therapy)
Number of subjects: 64
Study 35987083 — intervention group
Group type: EXPERIMENTAL
Intervention: MIACT
Number of subjects: 64
Study 35987083 — intervention group
Group type: COMPARATOR
Intervention: CC (Conventional Care)
Number of subjects: 64
Study 33962909 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel followed by abiraterone acetate plus prednisone (AA)
Number of subjects: 0
Study 33962909 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel followed by docetaxel
Number of subjects: 0
Study 32393158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid program combining the AFVP with principles of individual placement and support-supported employment
Number of subjects: 111
Study 32393158 — intervention group
Group type: COMPARATOR
Intervention: About Face Vocational Program (AFVP)
Number of subjects: 111
Study 36094935 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) counselling
Number of subjects: 461
Study 36094935 — intervention group
Group type: COMPARATOR
Intervention: Standard birth plan counselling
Number of subjects: 461
Study 36094935 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting BP to the hospital
Number of subjects: 461
Study 33143883 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptochloa fusca
Number of subjects: 6
Study 33143883 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachiaria mutica
Number of subjects: 6
Study 33143883 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg kg−1 Cr)
Number of subjects: 6
Study 33143883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr 25 mg kg−1
Number of subjects: 6
Study 33143883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr 50 mg kg−1
Number of subjects: 6
Study 33143883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr 100 mg kg−1
Number of subjects: 6
Study 35972855 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 0.25 mg with doravirine and lamivudine
Number of subjects: 121
Study 35972855 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 0.75 mg with doravirine and lamivudine
Number of subjects: 121
Study 35972855 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 2.25 mg with doravirine and lamivudine
Number of subjects: 121
Study 35972855 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined islatravir group
Number of subjects: 121
Study 35972855 — intervention group
Group type: COMPARATOR
Intervention: DOR/3TC/TDF
Number of subjects: 121
Study 35972855 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir (combined)
Number of subjects: 121
Study 35972855 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir with doravirine
Number of subjects: 121
Study 34375397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein-low-glycemic-index diet
Number of subjects: 1822
Study 34375397 — intervention group
Group type: COMPARATOR
Intervention: Moderate-protein-moderate-GI diet
Number of subjects: 1822
Study 35219379 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified full enteral nutrition
Number of subjects: 321
Study 35219379 — intervention group
Group type: COMPARATOR
Intervention: Full enteral nutrition
Number of subjects: 321
Study 35219379 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric enteral nutrition
Number of subjects: 321
Study 34955432 — intervention group
Group type: EXPERIMENTAL
Intervention: UJVIRA (Trastuzumab Emtansine)
Number of subjects: 168
Study 34955432 — intervention group
Group type: COMPARATOR
Intervention: Kadcyla (Trastuzumab Emtansine)
Number of subjects: 168
Study 33515786 — intervention group
Group type: EXPERIMENTAL
Intervention: Support of care managers (Cardiolotse)
Number of subjects: 2908
Study 33515786 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2908
Study 33920052 — intervention group
Group type: EXPERIMENTAL
Intervention: Home food availability of 100% fruit juice
Number of subjects: 2967
Study 33920052 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental role modeling of fruit intake
Number of subjects: 2967
Study 33920052 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvements in positive food parenting practices (FPPs) over time
Number of subjects: 2967
Study 33920052 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in negative food parenting practices (FPPs) over time
Number of subjects: 2967
Study 32252548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (110 mg)
Number of subjects: 2725
Study 32252548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (150 mg)
Number of subjects: 2725
Study 32252548 — intervention group
Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 2725
Study 35091321 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (PG)
Number of subjects: 66
Study 32471477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia
Number of subjects: 60
Study 32471477 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 34981829 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg every 2 weeks (Q2W)
Number of subjects: 331
Study 34981829 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg every 4 weeks (Q4W)
Number of subjects: 331
Study 34981829 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptitration to Secukinumab 300 mg every 2 weeks (Q2W)
Number of subjects: 331
Study 34981829 — intervention group
Group type: COMPARATOR
Intervention: Remaining on Secukinumab 300 mg every 4 weeks (Q4W)
Number of subjects: 331
Study 32178856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with 3 infection control link nurses and systematic audits and feedback
Number of subjects: 121
Study 32178856 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard multimodal approach
Number of subjects: 121
Study 32178856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups reported increased Compliance with Standard Precaution Scale Italian version scores
Number of subjects: 121
Study 32178856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 121
Study 35934140 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐10450232 (NTM‐006) single doses (50–6000 mg)
Number of subjects: 0
Study 35934140 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐10450232 (NTM‐006) multiple doses (250–2500 mg twice daily for 8 days)
Number of subjects: 0
Study 35934140 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐10450232 (NTM‐006)
Number of subjects: 0
Study 35934140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33813946 — intervention group
Group type: EXPERIMENTAL
Intervention: QLU-C10D health states from the EORTC QLQ-C30 questionnaire
Number of subjects: 2480
Study 33020030 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended pelvic lymph node dissection (PLND) templates
Number of subjects: 903
Study 33020030 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predicting LNI
Number of subjects: 903
Study 32453851 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular perceptual learning (n = 7)
Number of subjects: 25
Study 32453851 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular perceptual learning (n = 8)
Number of subjects: 25
Study 32453851 — intervention group
Group type: COMPARATOR
Intervention: Patching (n = 10)
Number of subjects: 25
Study 32453851 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (binocular, monocular, patching)
Number of subjects: 25
Study 36471258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg
Number of subjects: 90
Study 36471258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 90
Study 36471258 — intervention group
Group type: COMPARATOR
Intervention: Control (bupivacaine only)
Number of subjects: 90
Study 33278071 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol delivered via pMDI canister connected to AeroChamber MV spacer
Number of subjects: 24
Study 33278071 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol delivered via pMDI canister connected to Combihaler spacer
Number of subjects: 24
Study 33278071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of salbutamol respirable solution (5000 µg/mL) nebulized by Aerogen Solo connected to its T-piece
Number of subjects: 24
Study 33278071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of salbutamol respirable solution nebulized by Aerogen Solo connected to Combihaler spacer with 2 puffs salbutamol MDI (200 µg salbutamol) before nebulisation
Number of subjects: 24
Study 33278071 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI with both spacers
Number of subjects: 24
Study 33826036 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line AAP
Number of subjects: 1108
Study 33826036 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line AAP (AAP-PD)
Number of subjects: 1108
Study 33826036 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line AAP (patients with cardiovascular comorbidities)
Number of subjects: 1108
Study 33826036 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line AAP (AAP-PD) (patients with cardiovascular comorbidities)
Number of subjects: 1108
Study 32245781 — intervention group
Group type: EXPERIMENTAL
Intervention: High-hemoglobin group (targeting hemoglobin levels of 11-13 g/dl)
Number of subjects: 491
Study 32245781 — intervention group
Group type: COMPARATOR
Intervention: Low-hemoglobin group (targeting hemoglobin levels of 9-11 g/dl)
Number of subjects: 491
Study 32245781 — intervention group
Group type: EXPERIMENTAL
Intervention: High-hemoglobin group
Number of subjects: 491
Study 32245781 — intervention group
Group type: COMPARATOR
Intervention: Low-hemoglobin group
Number of subjects: 491
Study 35970302 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi‐cel)
Number of subjects: 0
Study 35970302 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC; salvage chemoimmunotherapy followed by high-dose therapy with autologous stem cell rescue)
Number of subjects: 0
Study 34793718 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate plus long-acting octreotide (7·4 GBq every 8 weeks, 30 mg intramuscularly)
Number of subjects: 231
Study 34793718 — intervention group
Group type: COMPARATOR
Intervention: High-dose long-acting octreotide (60 mg every 4 weeks)
Number of subjects: 231
Study 34793718 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate
Number of subjects: 231
Study 32521053 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary anastomosis
Number of subjects: 130
Study 32521053 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's procedure
Number of subjects: 130
Study 36246976 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral flexible ureteroscope holmium laser incision and drainage of parapelvic cyst
Number of subjects: 82
Study 36246976 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic parapelvic cyst topical decompression
Number of subjects: 82
Study 35831832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3:1 heating/cooling rate
Number of subjects: 20
Study 35831832 — intervention group
Group type: COMPARATOR
Intervention: 3:2 heating/cooling rate
Number of subjects: 20
Study 35831832 — intervention group
Group type: COMPARATOR
Intervention: 3:3 heating/cooling rate
Number of subjects: 20
Study 35831832 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 20
Study 32150072 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation with Respiratory Muscle Training (RMT)
Number of subjects: 21
Study 32150072 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation (Control)
Number of subjects: 21
Study 34194290 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation (NMES) in combination with traditional dysphagia therapy (TDT)
Number of subjects: 30
Study 34194290 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation in combination with traditional dysphagia therapy (TDT)
Number of subjects: 30
Study 34194290 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation (NMES)
Number of subjects: 30
Study 34194290 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 34194290 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation (NMES) and sham stimulation
Number of subjects: 30
Study 34389552 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based smartphone-supported high intensity interval training (HIIT)
Number of subjects: 50
Study 34389552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 33496028 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia group
Number of subjects: 184
Study 33496028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 33496028 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia group (with varying proteinuria levels)
Number of subjects: 184
Study 32379724 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC-AAT (first-generation intravenously administered RNA interference therapeutic)
Number of subjects: 0
Study 32379724 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-AAT (next-generation subcutaneously administered RNA interference therapeutic)
Number of subjects: 0
Study 34591237 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg every 3 weeks
Number of subjects: 152
Study 34591237 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy (investigator's choice of paclitaxel, docetaxel, or irinotecan)
Number of subjects: 152
Study 34591237 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 152
Study 34591237 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 152
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: PD1-positive CD4 cells (tumor)
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: PD1-positive CD4 cells (stroma)
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: PD1-positive CD8 cells (tumor)
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: PD1-positive CD8 cells (stroma)
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: PD1-positive CD8 cells (tumor+stroma)
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells (tumor)
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells (stroma)
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells (tumor+stroma)
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: PD1-positive CD4 cells (tumor+stroma)
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells
Number of subjects: 66
Study 33963012 — intervention group
Group type: EXPERIMENTAL
Intervention: PD1-positive CD4 cells
Number of subjects: 66
Study 32980623 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based blood pressure monitoring (implementation cohort)
Number of subjects: 436
Study 32980623 — intervention group
Group type: COMPARATOR
Intervention: Text-based blood pressure monitoring (trial cohort)
Number of subjects: 436
Study 34305809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage therapy
Number of subjects: 678
Study 34305809 — intervention group
Group type: COMPARATOR
Intervention: Regular-dosage therapy
Number of subjects: 678
Study 32507404 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific implant (PSI)
Number of subjects: 20
Study 32507404 — intervention group
Group type: COMPARATOR
Intervention: Calcium phosphate cement (C)
Number of subjects: 20
Study 35276863 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble cholecalciferol at a dose of 50,000 IU/week for 2 weeks, followed by 5000 IU/day for the rest of the study (n = 45)
Number of subjects: 128
Study 35276863 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble cholecalciferol at a dose of 2000 IU/day (n = 46)
Number of subjects: 128
Study 33146778 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose DEC (6 mg/kg body weight)
Number of subjects: 46
Study 32060257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-based anesthesia (Group S)
Number of subjects: 234
Study 32060257 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anesthesia (Group P)
Number of subjects: 234
Study 35323843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 362
Study 35323843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 362
Study 35323843 — intervention group
Group type: COMPARATOR
Intervention: Control group (CRVO)
Number of subjects: 362
Study 35915317 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus Cidan Capsule (0.27 g/capsule, 5 capsules every time, 4 times a day for 6 months)
Number of subjects: 249
Study 35915317 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 249
Study 35915317 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus Cidan Capsule
Number of subjects: 249
Study 34863208 — intervention group
Group type: EXPERIMENTAL
Intervention: Swap offer
Number of subjects: 550
Study 34863208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri‐Score labeling
Number of subjects: 550
Study 34863208 — intervention group
Group type: COMPARATOR
Intervention: Norm message
Number of subjects: 550
Study 32757149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral remimazolam 360 mg + 40% v/v alcohol
Number of subjects: 46